Acta medica portuguesa

Changes in Antidiabetic Drug Prescribing Across Regions in Portugal Over Eight Years (2017–2024)

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated

Abstract

The TREND-8 study identified significant changes in antidiabetic prescribing patterns in Portugal from 2017 to 2024.

  • There was a marked increase in the use of sodium-glucose cotransporter-2 inhibitors (SGLT2i).
  • Glucagon-like peptide-1 receptor agonists (GLP-1RA) also saw significant growth in prescribing rates.
  • The TREND-8 REGIONS study aimed to analyze variations in prescribing across different regions and healthcare settings.

Simplified

Full Text

Full text is available at the source.
View Full Text ↗

Related papers

Sep '22
Race and Ethnicity Linked to Use of New Diabetes Medicines in Veterans with Type 2 Diabetes
cited by 118 papers
comparative study
Jul '25
Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in South Korean Patients with Type 2 Diabetes and Heart Disease
top 20% journal
cited by 3 papers
journal article
Nov '25
Changing use of diabetes medicines by age, kidney health, and body weight in a nationwide study
top 5% journal
cited by 2 papers
journal article
Mar '21
Use of Blood Sugar Medicines in People with Heart Artery Disease
cited by 7 papers
journal article
Oct '25
Improving Diabetes Treatment in Primary Care
top 50% journal
multicenter study
Nov '24
Trends in prescribing diabetes drugs that lower blood sugar and protect heart and kidney health in South Korea from 2015 to 2021
top 20% journal
cited by 3 papers
journal article
Feb '20
Changes in Patient Features and Prescription Choices for Two Diabetes Drug Types from 2013 to 2018
top 1% journal
cited by 92 papers
historical article
Sep '25
Changes over time in diabetes medicine prescriptions for new type 2 diabetes patients in Spain
top 20% journal
observational study

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free

Recent issues from the glp-1 therapies brief

issue #54
GLP-1 drugs don't build habits — and that gap is costing patients their results
5 days ago7 studies
issue #53
Semaglutide slowed aging and extended lifespan in older female mice
1 week ago7 studies
issue #52
GLP-1 drugs linked to lower Parkinson's risk in people with type 2 diabetes
2 weeks ago7 studies
issue #51
Semaglutide linked to nearly double the risk of a rare eye condition in people with diabetes
3 weeks ago7 studies
issue #50
A once-daily pill beat placebo on weight loss — and it wasn't semaglutide
4 weeks ago7 studies
issue #49
GLP-1 drugs work even without weight loss — and scientists are finally mapping why
5 weeks ago7 studies
issue #48
Stop the drug, regain the weight: pooled data puts the average rebound at 7%
6 weeks ago7 studies
issue #47
The brain region that explains why blocking and activating the same receptor both cause weight loss
7 weeks ago7 studies
issue #46
GLP-1 drugs linked to lower depression and bipolar disorder risk in large genetic study
8 weeks ago7 studies
issue #45
Stopping GLP-1 drugs linked to higher depression and anxiety risk in type 2 diabetes patients
9 weeks ago7 studies
explore the archive
See more issues from the glp-1 therapies brief